Pyoderma gangrenosum
Pyoderma gangrenosum minangka penyakit kulit inflamasi sing langka ing ngendi pustula utawa nodul sing nyeri dadi ulkus sing terus berkembang. Pyoderma gangrenosum ora kena infeksi. Pangobatan bisa uga kalebu kortikosteroid, cyclosporin, utawa macem-macem antibodi monoklonal. Sanadyan bisa mengaruhi wong ing umur apa wae, umume mengaruhi wong ing umur 40 lan 50an.
☆ Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
Ing sikil saka wong karo ulcerative colitis.
References
Pyoderma gangrenosum minangka kondisi kulit langka sing nyebabake ulkus sing nyeri kanthi pinggiran abang utawa wungu. Iki diklasifikasikake minangka penyakit inflamasi lan minangka bagean saka klompok dermatosis neutrophilic. Panyebab pyoderma gangrenosum rumit, nglibatake masalah karo kakebalan bawaan lan adaptif ing wong sing rawan sacara genetis. Bubar, peneliti wis fokus ing folikel rambut minangka titik wiwitan potensial saka penyakit.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum minangka kondisi kulit langka sing nyebabake borok sing lara banget. Sanadyan kita ora ngerti sababe, kita ngerti yen iki kalebu kegiatan tambah sel kekebalan tartamtu. Nambani penyakit kasebut ora gampang. Kita duwe macem-macem obat sing nyuda sistem kekebalan utawa ngowahi kegiatane. Saliyane iki, kita uga fokus kanggo nambani tatu lan ngatur rasa nyeri. Kortikosteroid lan siklosporin asring dadi pilihan pisanan kanggo perawatan, nanging akhir-akhir iki, ana riset luwih akeh babagan nggunakake terapi biologis kaya inhibitor TNF-α. Biologis iki luwih disenengi, utamane ing pasien kanthi kondisi inflamasi liyane, lan digunakake sadurunge ing proses penyakit.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
